Approximately 10% of Medicare beneficiaries do not comply with their prescribed medication regimen because they simply cannot afford it, researchers from Harvard Medical School reported in the Journal of Cancer Survivorship. They added that elderly Medicare patients, whether or not they are being treated for cancer, commonly skip taking a pill so that they can last longer, or forgo filling a prescription completely because it is just too expensive. The authors believe that their findings suggest that seniors with cancer or those who survived it do not face greater medical costs than other patients. The rise in medication costs has occurred in parallel with an aging population, leading to greater financial burdens for the patient. Cancer costs have risen considerably. Patients being treated for cancer face considerable out-of-pocket expenses while they are being diagnosed, treated and receiving follow-up care.
As many as one in ten elderly people in the US, registered with Medicare, do not stick to their prescribed medication because it is too expensive, according to Dr. Larissa Nekhlyudov and colleagues from Harvard Medical School. Their work, funded by the National Institute on Aging and the National Cancer Institute, shows that cost-related medication non-adherence - skipping pills to make the medicine last longer, and not filling in a prescription because it is too expensive - is common among this group, whether or not they suffer from cancer. This suggests that elderly cancer survivors do not face a greater financial burden related to medical costs than those without cancer. The study is published online in Springer's Journal of Cancer Survivorship. As the population ages, the cost of medicines is rising and there is evidence that this has resulted in financial burden for patients.
The majority of patients with high-grade non-invasive bladder cancer are not getting the care recommended by official guidelines from the American Urology Association and the National Comprehensive Cancer Network; essential treatment to minimize the chances of a recurrence or cancer progression, researchers from UCLA's Jonsson Comprehensive Cancer Center revealed in the journal Cancer. The scientists say their findings are "alarming". In their study, only 1 bladder cancer patient received comprehensive recommended care out of a total of 4, 545. Dr. Karim Chamie explained that recommended care for this type of bladder cancer is crucial, because it significantly reduces mortality rates. Dr. Chamie said: "We were surprised by the findings in this study, particularly in an era when many suggest that doctors over-treat patients and do too much in the name of practicing defensive medicine.
Low Compliance To Guidelines By Physicians Resulting In Suboptimal Treatment Of Bladder Cancer Patients
A new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society has reported that low compliance by healthcare providers to the current guidelines for the treatment of high-grade noninvasive bladder cancer is resulting in incomplete care of patients with the disease. The researchers believe that there is a need to recognize and overcome hurdles in order to provide the highest quality care to patients with bladder cancer. Post treatment, high-grade noninvasive bladder cancer is known to recur and to progress to a more invasive tumor. Chance of recurring is up to 70% and of progression to more invasive form up to 50%. This makes optimal treatment for patients with the disease crucial. Subjects must undergo a number of surgeries if the tumor recurs in a noninvasive form.
New Report Reveals Low Treatment Uptake, Inadequate Implementation Of National Osteoporosis Guidelines And Poor Adherence To Therapy
New report reveals low treatment uptake, inadequate implementation of national osteoporosis guidelines and poor adherence to therapy In Europe, a serious treatment gap is leaving millions of people at high risk of fragility fractures. The findings were revealed in 'Osteoporosis: Burden, health care provision and opportunities in the EU', a landmark report prepared by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations (EFPIA). The report found that only a minority of high risk patients are receiving treatment to prevent fractures - contrary to the recommendations of most national osteoporosis guidelines and despite continued advances in risk assessment and the wide-spread availability of effective medication.